This approach offers a methodology paradigm and pathway for improving clinical outcomes, particularly in gynecologic and breast cancers with high PD-L1 and VISTA expression, thereby establishing an avenue in immune-oncology therapy. Here, CD274 is linked to breast carcinoma.